Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshitaka Hippo has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intracellular Molecular Dynamics Progressively Change during Carcinogenesis Revealed by Elastic and Quasi-Elastic Neutron Scattering

    by Daisuke Muto, Tatsuhito Matsuo, Tilo Seydel, Akiko Endo, Florian Turbant, Yoshitaka Hippo, Yusuke Suenaga, Judith Peters

    Cancer has traditionally been studied from molecular and genetic perspectives, and more recently, increasing attention has been directed toward its physical aspects. The intrinsically disordered proteome is altered in cancer cells compared to normal cells. Nevertheless, how the emergence of these proteins is associated with the intracellular physical environment remains unknown. Here, we investigated intracellular dynamics during tumorigenesis using normal, precancerous, and tumor-derived organoids by elastic incoherent neutron scattering (EINS) and quasi-elastic neutron scattering (QENS). EINS analysis revealed a decrease in atomic mean-square displacement from control to precancerous and tumor organoids. In contrast, QENS analysis demonstrated gradual decreases in both the elastic fraction and correlation time, indicating that a larger fraction of intracellular molecules undergoes faster motions during tumorigenesis. These findings suggest that the intracellular physical state is progressively remodeled during cancer development and provide a physical perspective of tumorigenesis.

  • PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways

    by Yali Xu, Hricha Mishra, Masataka Takahashi, Hajime Nishimura, Yusuke Suenaga, Wenkui Yu, Yoshitaka Hippo, Harukazu Suzuki, Xian-Yang Qin

  • Association between cesarean delivery and pediatric leukemia: A case-control study using a Japanese administrative claims database

    by Yohko Nakamura, Yoshihide Terada, Naoto Kaneko, Yoshitaka Hippo, Nobuaki Michihata

  • Open Access

    Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis

    by Xian-Yang Qin, Yali Xu, Hricha Mishra, Yohei Shirakami, Shiou-Hwei Yeh, Chiao-Ling Li, Kazushi Numata, Yusuke Suenaga, Feifei Wei, Reiko Ando, et al.

    Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. It is often diagnosed at advanced stages and characterized by high recurrence rates. Although chronic liver inflammation and metabolic dysfunction are established contributors to tumorigenesis, the molecular mechanisms that link microenvironmental stress to malignant transformation remain poorly understood. MYCN, a proto-oncogenic transcription factor, has emerged as a potential biomarker of cancer stemness. However, its role in hepatocarcinogenesis remains unclear. In this study, we elucidated the oncogenic role of MYCN and its dynamic transcriptional regulation during liver tumorigenesis. Using a hydrodynamic tail vein injection-based transposon system in mice, we demonstrated that MYCN overexpression synergizes with AKT activation to promote liver tumorigenesis. Transcriptomic profiling revealed that MYCN-driven tumors exhibited features of human HCC subtypes enriched in stress-adaptive transcriptional programs. Time-resolved spatial transcriptomics further uncovered a MYCN-enriched niche characterized by epithelial–mesenchymal transition (EMT) and Wnt/β-catenin signaling, which expanded during tumor progression and was spatially proximate to transformed malignant cells. To translate these findings to human HCC, we developed a machine learning-based MYCN niche score and validated its clinical relevance across multiple human HCC cohorts. This score reliably predicted recurrence risk and identified EMT-prone microenvironments, with stronger predictive performance in nontumor tissues, suggesting its potential in detecting precancerous niches predisposed to de novo tumorigenesis. Collectively, our findings establish MYCN as a functional driver and spatial marker of tumor-promoting microenvironments in liver tumorigenesis; additionally, we propose a clinically actionable strategy to identify high-risk patients through transcriptomic profiling of nontumor liver tissue.


  • Chemical Screening of RIKEN Natural Products Depository Identified a MYCN Expression Inhibitor Partially through HGF–MET Signaling Pathway

    by Yali Xu, Hricha Mishra, Hiroyuki Osada, Nobumoto Watanabe, Hiroyuki Hirano, Hajime Nishimura, Yutaka Furutani, Yusuke Suenaga, Yoshitaka Hippo, Wenkui Yu, et al.

    The oncogene MYCN is predominantly expressed in cancer stem-like cells, where it drives tumor growth, metastasis, and therapeutic resistance in hepatocellular carcinoma (HCC). In this study, we explored MYCN Inhibitors (MI) from the RIKEN Natural Products Depository chemical library and identified NPD15261 (designated as MI102) as a selective small-molecule inhibitor of MYCN expression. MI102 markedly reduced MYCN mRNA and protein levels in HCC cells, suppressing proliferation and colony formation, while inducing apoptosis, with minimal impact on normal hepatic cells. Mechanistically, kinase profiling revealed that MI102 is a highly selective inhibitor of MET receptor tyrosine kinase that specifically blocks phosphorylation at Y1234/Y1235. Hepatocyte growth factor-mediated MET activation induces MYCN expression and partially rescues MI102-mediated MYCN suppression. Notably, MI102 effect exhibited superior tumor cell selectivity compared with the MET inhibitor tivantinib. At the transcriptional level, RNA-seq revealed that MI102 globally downregulated MYCN-associated oncogenic programs. Collectively, these findings establish pharmacological downregulation of MYCN as a promising therapeutic strategy for HCC and reveal a functional link between MET signaling and MYCN-driven oncogenic pathways.


  • CCA-1.1 Destabilizes MYC proteins to induce irreversible anti-proliferative effects in hepatocellular carcinoma

    by Rohmad Yudi Utomo, Novia Permata Hapsari, Nadzifa Nugraheni, Beni Lestari, Mila Hanifa, Ni Putu Linda Laksmiani, Ummi Maryam Zulfin, Daisuke Muto, Muthi Ikawati, Yusuke Suenaga, et al.

    N-Myc and c-Myc, as two major members of the MYC family proteins, independently contribute to hepatocellular carcinoma (HCC) by promoting proliferation, survival, and metabolic reprogramming. Overexpression of both proteins correlates with poor clinical outcomes, while intrinsic structural disorder hinder direct pharmacological targeting of MYC proteins. CCA-1.1 exhibits enhanced biological and physicochemical properties over its parent compound, curcumin, and demonstrates potent anti-cancer activity in various cancer types. We aim to investigate the anti-proliferative activity of CCA-1.1 through modulation of the MYC proteins and induction of cell cycle arrest and/or cell death mechanisms, including senescence, apoptosis, and autophagy. CCA-1.1 exhibited potent and irreversible anti-proliferative activity on Huh-6 cells by inhibiting EGFR kinase activity and its downstream signalling. CCA-1.1 also promoted G2/M arrest, induced apoptosis, and generated senescence. At the molecular level, CCA-1.1 downregulated N-Myc and c-Myc protein levels through the promotion of GSK3β activation and suppression of NCYM, a stabilizer protein of N-Myc. Furthermore, CCA-1.1 activated autophagy as a result of MYC protein destabilization. CCA-1.1 exerts a multi-faceted anti-cancer effect in MYCN-expressed HCC cells by inhibiting kinase signalling and destabilizing MYC proteins, leading to apoptosis, senescence, and autophagy. Molecular docking and molecular dynamic simulation revealed that CCA-1.1 interacted with both N-Myc and c-Myc. Our findings demonstrate CCA-1.1 as a distinctive anti-cancer candidate for HCC driven by MYC activation.


  • Open Access

    IGF2BP3 is essential for the growth heterogeneity of colorectal adenoma cells by regulating MYC

    by Tomohiko Sunami, Roberto Coppo, Kunishige Onuma, Jumpei Kondo, Hiroyuki Uematsu, Daisuke Hoshi, Yoshihiro Yamamoto, Osamu Kikuchi, Shinya Ohashi, Yasuhide Takeuchi, et al.

    Adenoma is a major precancerous lesion in colorectal cancer (CRC), and the adenoma-carcinoma sequence is a well-known multistep progression to CRC caused by the accumulation of genetic mutations. On the other hand, the non-genetic mechanisms in the adenoma-carcinoma sequence remain largely unknown. In this study, organoids were established from 31 colorectal adenomas from 19 patients. Some adenomas showed heterogeneity in the proliferative potential of single cells, and this heterogeneity was regulated by non-genetic mechanisms. IGF2BP3 was identified as a differentially expressed gene between organoids with different growth patterns. IGF2BP3 positively regulated MYC expression at the transcriptional level and negatively regulated it at the translational level. This promoted high proliferative potential with high levels of oxidative phosphorylation, while allowing cells to avoid MYC-induced cell death. IGF2BP3 affected the tumorigenicity of mouse adenomas in vivo. Intra-tumor heterogeneity in growth potential is acquired at the precancerous stage in the adenoma-carcinoma sequence of colorectal carcinogenesis, and IGF2BP3 plays an important role in regulating MYC levels. These findings provide new insights into the non-genetic regulation of adenomas during CRC development.

  • Open Access

    Discovery of pyroptosis-inducing natural products in neuroblastomas: computational studies with experimental validation

    by Beni Lestari, Rohmad Yudi Utomo, Faaza Aulia Rahman, Dyaningtyas Dewi Pamungkas Putri, Ummi Maryam Zulfin, Yusuke Suenaga, Edy Meiyanto, Yoshitaka Hippo

    Neuroblastomas evade apoptosis due to oncogene mutations and antiapoptotic proteins, necessitating novel therapeutics that work in concert with other forms of cell death. Pyroptosis has potential as a strategic cell death mechanism in neuroblastoma. This study aimed to identify compounds that modulate pyroptosis, specifically those that target gasdermin D (GSDMD) oligomerization. The study employed computational analysis and in vitro screening. The COCONUT database provides the natural compound dataset. Drug-likeness analysis and pharmacophore fitting were applied to screen potential GSDMD oligomerization modulators. Hit compounds underwent molecular docking with MOE and molecular dynamic (MD) simulations with NAMD 2.14 to analyse structural changes. The computational screening results were corroborated by in vitro assays, including the WST-8 assay, Western blot, and immunofluorescence, which target pyroptosis-specific caspase-1. Pharmacophore fitting, molecular docking, and molecular dynamics simulations identified the top five compounds, namely, quercetin, naringenin, hesperetin, curcumin, and galangin, as potent modulators of GSDMD oligomerization. Among these compounds, curcumin, quercetin, and galangin exerted potent cytotoxic effects on GSDMD-expressing neuroblastoma SK-N-AS cells, with IC50 values of 21, 37, and 49 µM, respectively. Curcumin and quercetin also promoted apoptosis via increased caspase-3 cleavage and reduced procaspase-7 and -8 levels, as shown by immunoblotting. Curcumin and galangin upregulated caspase-1 expression, as demonstrated by the detection of a fluorescent-labelled inhibitor of caspase-1 by immunostaining, suggesting that these two compounds could induce pyroptosis. Hesperetin and naringenin showed low cytotoxicity, had no effect on caspase activation, and did not exhibit signs of pyroptosis in SK-NA-S cells. Our study successfully identified curcumin as a strong regulator of both apoptosis and pyroptosis, quercetin as a strong modulator of apoptosis, and galangin as a strong modulator of pyroptosis. Further research on these compounds is crucial for the development of novel therapeutic strategies for neuroblastoma treatment.


  • Right versus left lung cancer: Findings from the Japanese cancer registry database

    by Nobuaki Michihata, Aya Washio, Yoshihide Terada, Naoto Kaneko, Yohko Nakamura, Yoshitaka Hippo